FATE
NASDAQ
$2.83
Fate Therapeutics Inc (FATE)
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders globally. The company is headquartered in San Diego, California.
Sector:
Healthcare
Industry:
Biotechnology
Buy
Target: $5.41 (+91.17%)
Market Cap
$348M
Free Cash Flow Yield
-31.09%
Beta (5Y)
1.33
Price Chart
Valuation
Market Cap$348M
P/S55.18
P/B1.94
Profitability
Total Revenue (TTM)$6.32M
Gross Profit (TTM)-$81M
EBITDA-$127M
Operating Margin-2540%
EPS-$1.13
Financial Health
Free Cash Flow Yield-31.09%
Growth & Risk
EPS 5Y CAGR-11.58%
Revenue 5Y CAGR-30.89%
FCF 5Y CAGR+17.88%
Beta (5Y)1.33
Sharpe Ratio1.34